U.S. Tech Hardware Stock News

GSI Technology (GSIT) has just posted its Q3 2026 scorecard, with recent quarters showing revenue around US$6.4 million in Q2 2026 and a basic EPS loss of US$0.11, while the trailing twelve months reflect a basic EPS loss of US$0.43 and net income losses of US$11.66 million. Over the past six reported quarters, revenue has moved from US$4.55 million in Q2 2025 to US$6.44 million in Q2 2026, while basic EPS has ranged from a profit of US$0.04 in Q1 2025 to losses between US$0.08 and US$0.21...

Healthpeak Properties (NYSE:DOC) has appointed Omkar Joshi as Head of Enterprise Innovation. Joshi, a former Palantir executive, will lead technology, automation, and data initiatives across the company. The move signals a stronger push toward digital transformation and operational efficiency at Healthpeak Properties. Healthpeak Properties, trading at $17.24, has seen mixed share performance, with a 7.2% return over the past 30 days and a 6.4% return year to date, alongside a 10.3% decline...

Red River Bancshares (RRBI) just posted its FY 2025 third quarter numbers, reporting total revenue of US$31.3 million and basic EPS of US$1.63, supported by net income of US$10.8 million. The company has seen quarterly revenue move from US$27.6 million in Q3 2024 to US$31.3 million in Q3 2025, while basic EPS has gone from US$1.28 to US$1.63 over the same period, with trailing twelve month EPS at US$6.04 and net income at US$40.7 million. With a trailing net profit margin of 34.1% and a...

If you are wondering whether PulteGroup's current share price still offers value, you are not alone. The stock has attracted a lot of attention from investors checking if the homebuilder is priced fairly. PulteGroup's share price last closed at US$125.09, with returns of negative 0.1% over 7 days, 6.7% over 30 days, 5.1% year to date, 10.8% over 1 year and a very large gain over 3 and 5 years. Recent coverage has focused on PulteGroup within the US homebuilding sector, as investors track how...

Hanover Bancorp (HNVR) has laid out its FY 2025 scorecard with fiscal third quarter revenue of US$16.7 million and EPS of US$0.47, alongside trailing twelve month revenue of US$68.0 million and EPS of US$1.52, giving investors a clear read on recent earnings power. Over the past year, the company has seen revenue move from US$59.8 million to US$68.0 million on a trailing basis, while trailing EPS shifted from US$1.66 to US$1.52. This sets the backdrop for a conversation about how its 16.2%...

Ecolab (NYSE:ECL) is reporting strong momentum in its Digital and Global High-Tech segments. These technology focused businesses are expanding even as the company faces tariff related inflation and softer demand in some areas. The mix of growth in high tech offerings and external cost pressures is a key theme for investors tracking Ecolab's next phase. Ecolab, trading at $281.99, is putting more weight behind its digital and high tech solutions at a time when parts of its portfolio are...

MetroCity Bankshares (MCBS) has reported Q3 FY 2025 results with total revenue of US$38.5 million and basic EPS of US$0.68, alongside net income of US$17.3 million, giving investors a fresh read on the bank’s earnings power. The company has seen trailing twelve month revenue shift from US$126.4 million in Q2 2024 to US$147.3 million in Q3 2025, with EPS over that same trailing window moving from US$2.15 to US$2.62. This sets up a results season where margins and earnings quality are front of...

Utah Medical Products (UTMD) closed FY 2025 with Q4 revenue of US$9.0 million and basic EPS of US$0.80, setting the tone for a year where earnings and sales moved within a relatively tight range. Over the past six quarters, quarterly revenue has run between US$9.0 million and US$10.0 million while basic EPS has ranged from about US$0.80 to US$1.02. This gives investors a clear look at how top line and EPS have tracked together through FY 2024 into FY 2025. With trailing net margins easing and...

ANI Pharmaceuticals recently reported revenue growth of 53.60% and continues to broaden its product portfolio and distribution channels, drawing strong interest from analysts and investors alike. With seven buy ratings and widespread optimism about its expanding business footprint, the company’s position within the pharmaceutical sector is gaining increased attention. Next, we’ll examine how ANI Pharmaceuticals’ rapid revenue growth shapes its investment narrative and what it could mean for...

Rhinebeck Bancorp (RBKB) has just posted its FY 2025 numbers, with fourth quarter revenue of US$13.0 million and EPS of US$0.22, while over the trailing twelve months revenue came in at US$51.7 million and EPS reached US$0.93. The company has seen revenue move from US$25.9 million and an EPS loss of US$0.80 over the trailing year to Q4 2024 to US$51.7 million and EPS of US$0.93 over the latest trailing period, giving investors a clear set of revenue and EPS figures to weigh. With a net...

Flagstar Bank National Association (FLG) has just posted another loss for Q3 2025, reporting total revenue of US$481 million and a net loss of US$45 million, or EPS of US$0.11. This keeps the full year firmly in loss making territory so far. Over recent periods the bank has seen revenue move from US$281 million in Q2 2024 to US$381 million in Q3 2024, then to US$480 million in Q4 2024, and US$411 million, US$432 million and US$481 million across Q1 to Q3 2025. Quarterly EPS has ranged between...

How Eastman Chemical's FY 2025 Numbers Set Up the Next Part of the Story Eastman Chemical (EMN) has wrapped up FY 2025 with fourth quarter revenue of US$1,973 million, Basic EPS of US$0.92 and net income excluding extraordinary items of US$105 million. The trailing twelve months show revenue of US$8.75 billion, Basic EPS of US$4.13 and net income of US$474 million. Over the past few quarters, the company has reported revenue moving from US$2,464 million in Q3 2024 to US$1,973 million in Q4...

Kingsoft Cloud Holdings (KC) is back on traders’ screens after a mix of operational updates, including year over year revenue growth, a narrower GAAP loss, and an upgraded Xingliu AI platform with expanded training, inference, and robotics capabilities. See our latest analysis for Kingsoft Cloud Holdings. The recent Xingliu AI upgrade and RSU grants have come against a backdrop of strong short term momentum, with a 30 day share price return of 27.76% and a year to date share price return of...

Earlier this week, the Centers for Medicare & Medicaid Services proposed a near-flat 2027 payment increase for Medicare Advantage plans, well below industry expectations and raising concerns about revenue pressure for insurers such as CVS Health. Alongside the modest rate proposal, CMS suggested risk-score and billing changes that could further affect how CVS’s Aetna business is reimbursed for Medicare Advantage members. We’ll now examine how this unexpectedly small Medicare Advantage rate...

Allegiant Travel Company recently reported its December, fourth-quarter, and full-year 2025 operating statistics, showing year-on-year increases in passengers, available seat miles, and revenue passenger miles, with load factors broadly stable despite slight full-year softening. The company also set a February 4, 2026 conference call to discuss its fourth-quarter and full-year 2025 financial results, signaling that management will soon frame these traffic trends within a broader financial...

Event context and recent stock performance Marcus & Millichap (MMI) has been drawing investor attention after recent share price moves, with the stock up about 0.8% over the past day and 2.5% over the past week. Those gains contrast with a small decline over the past month and a roughly 6.9% decline over the past 3 months, raising questions about how short term momentum lines up with the company’s underlying fundamentals. See our latest analysis for Marcus & Millichap. Stepping back, the...

On January 22, 2026, First Industrial Realty Trust refinanced and amended its major unsecured term loans, extending maturities into 2029 and 2030, expanding capacity on one facility to US$375 million, and removing a 10 basis point SOFR adjustment while keeping the loans interest-only. The revised agreements also introduce potential sustainability-linked pricing and tighten covenant structures, reshaping the REIT’s funding profile and flexibility for future capital allocation decisions. Next,...

If you are wondering whether Ralliant's current share price gives you good value for your money, you are not alone. This article is built to help you assess that. Over the short term, the stock has seen a 1.4% decline over the past week, a 4.0% gain over the last 30 days and a 3.4% return year to date, which has likely caught the attention of investors tracking short term moves. Recent coverage has focused on Ralliant's position in the tech sector and how investors are reacting to its latest...

Church & Dwight (CHD) just posted its FY 2025 third quarter numbers, with revenue of US$1,585.6 million and basic EPS of US$0.75, alongside net income of US$182.2 million. The company has seen quarterly revenue move from US$1,511.2 million in Q2 2024 to US$1,582.0 million in Q4 2024 and then to US$1,585.6 million in Q3 2025. Over the same periods, basic EPS shifted from US$1.00 to US$0.77 and then to US$0.75, creating a picture in which the headline growth story is now as much about how...

Why Barrick Mining is on investors’ radar today Barrick Mining (NYSE:B) is drawing attention after a year in which its total return sits around 186%, alongside recent one day and past week share price declines that may have some investors reassessing their timing. See our latest analysis for Barrick Mining. The recent 1 day and 7 day share price returns of 12.03% and 10.36% declines contrast with a 39.60% 90 day share price return and a 1 year total shareholder return of 185.63%. This...

Brown & Brown, Inc. recently reported full-year 2025 results, with revenue rising to US$5.90 billion and net income reaching US$1.05 billion, while also declaring a regular quarterly dividend of US$0.165 per share payable on February 11, 2026. The mixed quarter highlighted rising adjusted earnings alongside a revenue shortfall and weaker organic growth, all against the backdrop of integrating its largest-ever acquisition and managing leadership changes following the passing of its Chief...

On 29 January 2026, Fractyl Health reported positive six-month randomized midpoint data from its REMAIN-1 study, showing Revita-treated patients had less weight regain and better cardiometabolic markers than sham after stopping GLP-1 drugs, and outlined plans to seek FDA De Novo classification. An interesting angle is that Revita is being explored specifically as a tool to help maintain weight loss after GLP-1 discontinuation, targeting a growing clinical gap. Against this backdrop, we’ll...

In January 2026, Curant Health's Curant Rare announced a collaboration with Cencora to offer an integrated commercialization solution for rare disease therapies, combining Cencora’s logistics, pharmacovigilance and market access support with Curant Rare’s specialty pharmacy and patient engagement services. A distinctive aspect of this partnership is its focus on real-world evidence and patient-reported outcomes, aiming to improve both market access and the overall patient experience in rare...

In recent weeks, Camtek has attracted heightened attention as analysts anticipate year-over-year gains in earnings and revenue ahead of its upcoming results, while the stock has outperformed both its sector and the broader market over the past month. What stands out is that, even with a current Zacks Rank of Hold and some valuation concerns, analyst estimate revisions and an overall “Outperform” consensus suggest growing confidence in the company’s business health and profitability. With...